Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Leipzg, Germany Clinical Trials

A listing of Leipzg, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (67) clinical trials

Stellarex Vascular E-Registry

Prospective, international, multi-center, single arm, observational study to continue to assess the treatment by the Stellarex OTW Drug-coated Angioplasty Balloon in superficial femoral and/or popliteal arteries according to the Instructions for Use in a broad, real-world, claudicant or ischemic rest pain patients population per the institution's standard practice.

Phase N/A

0.0 miles

Learn More »

EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits With DuraGraft [VASC]

Objectives (i) To evaluate the Safety and Performance of DuraGraft (ii) To characterize the use of DuraGraft and the outcomes of patients whose vascular grafts were treated with DuraGraft in daily clinical routine (iii) To further characterize the incidence of MACCE outcomes associated with CABG in patients whose vascular grafts …

Phase N/A

0.0 miles

Learn More »

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)

Recombinant hyaluronidase is an established therapeutic principle to facilitate the infusion of large volumes of fluids subcutaneously (e.g. Ringer solution and antibodies such as IG, rituximab, trastuzumab). HyQvia is a product consisting of recombinant human hyaluronidase (rHuPH20, Hylenex), and a human normal immunoglobulin (IG). The subcutaneous (SC) IG is a …

Phase N/A

0.0 miles

Learn More »

Lifetech LAmbre Left Atrial Appendage (LAA) Closure System Post-Market Clinical Follow-up

Atrial fibrillation (AF) is the most common cardiac arrhythmia causing ischemic stroke. The CHA2DS2-VASc score was developed to estimate the stroke rate in patients with non-valvular AF, and high scores predict a raised annual stroke risk. The yearly stroke risks without treatment in patients with CHA2DS2-VASc score 2 and 9 …

Phase N/A

0.0 miles

Learn More »

Evaluation of Peripheral EOS for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding

Prospective, non-randomized, multi-center confirmatory observational study for the treatment of subjects with the need for vascular occlusion for the following conditions: 1. Stopping blood loss from a damaged blood vessel from a traumatic vascular injury 2. Hemorrhage caused by a neoplasia 3. Neoplastic process (tumor) 4. Gastrointestinal bleeding 5. Closing …

Phase N/A

0.0 miles

Learn More »

Risk Stratification in Severe Treatment-naive Tricuspid Regurgitation

This registry is aimed to characterize patients with severe tricuspid regurgitation for the purpose of patient selection for interventional treatment and identify factors related to adverse outcomes.

Phase N/A

0.0 miles

Learn More »

Retrospective Follow-up of BIOLUX P-I/-II

The aim is to collect long-term clinical data from 132 patients from Belgium, Germany and Austria who had previously participated in either of the BIOLUX P-I or P-II studies. Patients in these studies were treated with either a percutaneous transluminal angioplasty (PTA) balloon catheter or a drug-coated Passe-18-Lux balloon (DCB). …

Phase N/A

0.0 miles

Learn More »

Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions

The main aim of this study is to investigate the change in asthma control after 6 months of therapy in patients treated with benralizumab biologic therapy for severe eosinophilic asthma under real-life conditions in a pulmonary care setting in Germany. The study also aims to investigate Quality-of-Life (QoL), the early …

Phase N/A

0.0 miles

Learn More »

PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE

Elevation of cardiac troponin can be found in about 30% of patients with acute ischemic stroke (depending on the assay used). Elevated troponin indicates increased mortality in stroke patients. There is currently little evidence regarding the ideal care of these patients. The investigators know from previous studies that approximately 25% …

Phase N/A

0.0 miles

Learn More »

Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF

Heart failure (HF) currently affects app. 2% of the western population and app. 10% of people >75 years. In about 50% of patients with symptomatic HF ejection fraction (EF) is preserved (HF-PEF). Once patients develop symptoms, the prognosis is poor with 25% mortality at 1 year and 50% mortality at …

Phase N/A

0.0 miles

Learn More »